Login to Your Account



Third Time's the Charm

Once-Weekly Bydureon Wins Long-Awaited FDA Approval

By Jennifer Boggs
Managing Editor

Monday, January 30, 2012
Amylin Pharmaceuticals Inc. can (finally) put another check in the win column, with the FDA's approval of Bydureon, a once-weekly version of exenatide, a move that puts the San Diego-based biotech on solid footing for a lucrative ex-U.S. partnering deal – even a potential buyout isn't out of the question.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription